ConforMIS Inc. (NASDAQ:CFMS) was up 4% during mid-day trading on Monday . The stock traded as high as $8.07 and last traded at $7.99, with a volume of 67,356 shares traded. The stock had previously closed at $7.68.

Several equities research analysts have issued reports on CFMS shares. JPMorgan Chase & Co. cut their target price on ConforMIS from $11.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, August 9th. Oppenheimer Holdings Inc. raised their target price on ConforMIS from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 9th. Zacks Investment Research cut ConforMIS from a “hold” rating to a “sell” rating in a research note on Tuesday, June 7th. Wells Fargo & Co. cut ConforMIS from an “outperform” rating to a “market perform” rating in a research note on Friday, May 13th. Finally, Deutsche Bank AG cut their target price on ConforMIS from $26.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, May 13th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $15.40.

The stock’s market capitalization is $337.44 million. The company has a 50-day moving average of $7.59 and a 200-day moving average of $8.87.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. During the same period last year, the firm earned ($2.51) EPS. The firm had revenue of $19.30 million for the quarter, compared to analysts’ expectations of $18.02 million. ConforMIS’s revenue was up .5% compared to the same quarter last year. Equities research analysts predict that ConforMIS Inc. will post ($1.40) EPS for the current year.

In other news, Director Kenneth P. Fallon III sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $8.44, for a total transaction of $33,760.00. Following the sale, the director now owns 92,222 shares of the company’s stock, valued at approximately $778,353.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.